A strategy for systemic delivery of the oncolytic herpes virus HSV1716: redirected tropism by antibody-binding sites incorporated on the virion surface as a glycoprotein D fusion protein-Reference-Cited by-同舟云学术

A strategy for systemic delivery of the oncolytic herpes virus HSV1716: redirected tropism by antibody-binding sites incorporated on the virion surface as a glycoprotein D fusion protein

Published:2008-08-14 Issue:24 Volume:15 Page:1579-1592
ISSN:0969-7128
Container-title:Gene Therapy
language:en
Short-container-title:Gene Ther

Author:

Conner J,Braidwood L,Brown S M

Publisher

Springer Science and Business Media LLC

Subject

Genetics,Molecular Biology,Molecular Medicine

Link

http://www.nature.com/articles/gt2008121.pdf

Reference48 articles.

1. Aghi M, Martuza RL . Oncolytic viral therapies-the clinical experience. Oncogene 2005; 24: 7802–7816.

2. Chiocca EA . Oncolytic viruses. Nat Rev Cancer 2002; 2: 938–950.

3. MacLean AR, Fareed MU, Robertson L, Harland J, Brown SM . Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence related sequences in Glasgow strain 17+ between immediate early gene 1 and the ‘a’ sequence. J Gen Virol 1991; 72: 631–639.

4. Brown SM, Harland J, MacLean AR, Podlech J, Clements JB . Cell type and cell state determine differentiated in vitro growth of non-neuroviulent ICP34.5-negative herpes simplex virus. J Gen Virol 1994; 75: 2367–2377.

5. Brown SM, MacLean AR, McKie EA, Harland J . The herpes simplex virus virulence factor ICP34.5 and the cellular protein MyD116 complex with proliferating cell nuclear antigen through the 63-amino acid domain conserved in ICP34.5, MyD116 and GADD34. J Virol 1997; 71: 9442–9449.

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging delivery strategy for oncolytic virotherapy;Molecular Therapy: Oncology;2024-06

2. HSV1716 Prevents Myeloma Cell Regrowth When Combined with Bortezomib In Vitro and Significantly Reduces Systemic Tumor Growth in Mouse Models;Viruses;2023-02-22

3. The Dilemma of HSV-1 Oncolytic Virus Delivery: The Method Choice and Hurdles;International Journal of Molecular Sciences;2023-02-12

4. Inconsistencies in Modeling the Efficacy of the Oncolytic Virus HSV1716 Reveal Potential Predictive Biomarkers for Tolerability;Frontiers in Molecular Biosciences;2022-06-15

5. Nanobugs as Drugs: Bacterial Derived Nanomagnets Enhance Tumor Targeting and Oncolytic Activity of HSV‐1 Virus;Small;2022-01-25